title: Vascular endothelial growth factor concentrations in aqueous humor before and after subconjunctival injection of bevacizumab for neovascular glaucoma.
authors.forename: Masanori
authors.initials: M
authors.lastname: Mizote
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Baba
authors.forename: Kazuyuki
authors.initials: K
authors.lastname: Hirooka
authors.forename: Hidetaka
authors.initials: H
authors.lastname: Yamaji
authors.forename: Fumio
authors.initials: F
authors.lastname: Shiraga
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D001082:Aqueous Humor / Q000378:metabolism*; D000068258:Bevacizumab; D003228:Conjunctiva; D005260:Female; D015355:Glaucoma, Neovascular / Q000188:drug therapy* / Q000378:metabolism*; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D014130:Trabeculectomy; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000378:metabolism*
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab